Market Insights Reports

Oral Thin Films Market Overview Oral drug delivery technologies form an integral part of the pharmaceutical industry. From the conventional tablets / capsules to modern-day fast disintegrating and rapidly acting tablets / films, the market has come a long way. Lower bioavailability of oral solid drugs, inconvenience of administering injections, inaccurate dosing by liquid formulations have turned the focus of pharmaceutical companies to develop novel oral dosage forms that eliminate several k

...read more

Dendritic Cell Therapies Market Overview The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body’s own immune system or its components to fight cancer. It is a relatively new concept, with the only success being targeted antibody based therapeutics (including monoclonal and conjugated antibodies). These antibody based drugs are passive immunotherapeutics. There has been a surge of interest in other classes of active immunotherapeutics incl

...read more

Inner Ear Diseases Market Overview A significant proportion of the world’s population is suffering from otologic diseases. Absence of any disease modifying drugs is a big unmet need in the market. The current treatment of inner ear diseases is primarily based on counselling, electric and magnetic nerve stimulations. At the same time, there is a growing off-label use of drugs for symptomatic relief. Cochlear implants, brainstem implants and hearing aids are other commonly available optio

...read more

Novel Hypercholesterolemia Drugs Market Overview Worldwide statistics indicate that there is a high cholesterol burden despite the presence of many cholesterol-lowering drugs in the market. Out of all the available options, statins have been ubiquitously prescribed over the last 25 years. Researchers have concluded that reduction of plasma LDL cholesterol (LDLC) is the cornerstone of assessing heart risk. Irrespective of baseline cholesterol concentration, each mmol/L LDLC reduction translate

...read more

Glycated Haemoglobin Testing Market Overview Diabetes is a chronic disease growing at an alarming rate across the globe. Over 382 million people are estimated to be currently suffering from the disease; the number is likely to increase to 592 million by 2035. With a very high prevalence, especially in some regions such as China and India, an increasing proportion of diabetic patients are likely to benefit from more efficient and accurate diagnostic tests in the future. Furthermore, an effi

...read more

Oral Oncolytics Market Overview Targeted therapeutics is fast emerging as the key focus area in biopharmaceutical industry. Oral targeted therapeutics has attracted many drug developers due to the ease of administration it offers to patients (especially pediatric and geriatric patients). In the case of leukemia, current marketed oral drugs include Gleevec, Tasigna, Sprycel, Bosulif, Imbruvica and Iclusig. The high price of these drugs still remains a major constraint to the market growth.

...read more

Dry Eye Syndrome Overview With nearly 300 million dry eye sufferers worldwide, dry eye represents one of the largest ophthalmic indications. It is also known as keratoconjunctivitis sicca. To date, there is no cure for dry eye syndrome, but there are treatments to control its symptoms. The prevalence of dry eye syndrome primarily increases with age, and has an estimated incidence of 15% in persons over the age of 65 years. A greater risk of acquiring dry eye is also experienced by females, wi

...read more

KRAS Market Overview The NRAS, HRAS and KRAS market is estimated to be worth $73 million in 2021 and is expected to grow at CAGR of 53.6% during the forecast period. Close to 10 million fatalities reported in 2020 were observed to be associated with cancer, which is believed to be one of the leading causes of death, globally. One of the primary reasons for the high mortality rate associated with this condition is anticipated to be late diagnosis, which eventually results in delayed treat

...read more
  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry